Clinical Trial Update: Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC) [Phase 1]

View source ↗

Summary

A Phase 1 safety study of ARQ 197 (tivantinib) in cirrhotic patients with hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hepatocellular Carcinoma

Drugs mentioned

• ARQ 197 (tivantinib)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Cirrhosis, Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED